Meningiomas expressing and responding to cholecystokinin (CCK)

J Neurooncol. 2005 Jul;73(3):199-204. doi: 10.1007/s11060-004-5177-2.

Abstract

The effect of cholecystokinin (CCK) on cultured human meningioma derived cells was investigated. Exposure of meningioma cells for 6-12 days to CCK-8s (2-200 nM) resulted in a dose dependent stimulation of cell growth to a maximum of 1.1-fold over basal controls. A time course study showed stimulation of cell growth at day 3 followed by increase throughout day 6. The stimulatory effect of CCK on meningioma cell growth was completely abolished by a CCK-B specific receptor antagonist, L-365,260. Reverse-transcription of meningioma-derived RNA into cDNA followed by amplification by the polymerase chain reaction using specific primers for CCK peptide and its CCK-A and/B receptor revealed 100% presence of CCK peptide and CCK-B receptors mRNA whereas CCK-A receptor was expressed in 66% of the meningiomas. These results provide evidence that human meningioma cells possess CCK peptide and its receptors the activation of which leads to increase of cell growth possibly via an autocrine/paracrine mechanism.

MeSH terms

  • Adult
  • Base Sequence
  • Benzodiazepinones / pharmacology
  • Cell Proliferation / drug effects
  • Cells, Cultured
  • Cholecystokinin / genetics
  • Cholecystokinin / metabolism*
  • Cholecystokinin / pharmacology*
  • Female
  • Humans
  • Male
  • Meningeal Neoplasms / genetics
  • Meningeal Neoplasms / metabolism*
  • Meningioma / genetics
  • Meningioma / metabolism*
  • Middle Aged
  • Molecular Sequence Data
  • Phenylurea Compounds / pharmacology
  • RNA, Messenger / analysis
  • Receptors, Cholecystokinin / antagonists & inhibitors
  • Receptors, Cholecystokinin / metabolism
  • Reverse Transcriptase Polymerase Chain Reaction
  • Time Factors

Substances

  • Benzodiazepinones
  • Phenylurea Compounds
  • RNA, Messenger
  • Receptors, Cholecystokinin
  • L 365260
  • Cholecystokinin